Akili, Inc.

Akili, Inc. (Nasdaq: DNAA) is a digital therapeutics company that entered the public markets in 2022 through a SPAC business combination, filing an S-1 registration statement on August 24, 2022. Operating in the digital health and prescription digital therapeutics sector, Akili develops regulated software-based treatments targeting cognitive disorders, including attention-deficit/hyperactivity disorder. The company's lead product received FDA authorization as a prescription digital therapeutic prior to its public listing, representing a significant regulatory milestone in the digital medicine space. The S-1 filing registered securities in connection with the completed business combination and formalized the company's standing as a publicly traded entity. For full deal data, filing history, and status tracking on DNAA and thousands of other SPAC transactions, sign up for complete access at SpacDesk.